GI
LRMR icon

GAMMA Investing’s Larimar Therapeutics LRMR Stock Holding History

GAMMA Investing’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.92K Sell
1,941
-781
-29% -$3.1K ﹤0.01% 3402
2026
Q1 		$12.2K Buy
2,722
+1,507
+124% +$6.02K ﹤0.01% 2967
2025
Q4 		$4.63K Buy
+1,215
New +$4.72K ﹤0.01% 3319
2024
Q4 		– Sell
-44
Closed -$288 – 3809
2024
Q3 		$288 Buy
+44
New +$354 ﹤0.01% 3460

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

GAMMA Investing's LRMR Position: Q2 2026 in Review

GAMMA Investing reduced its Larimar Therapeutics (LRMR) stake by 29% in Q2 2026, selling an estimated $3.1K and leaving 1,941 shares worth $5.92K. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

GAMMA Investing first reported a position in LRMR in Q3 2024 and has held it in 4 quarters since. The position peaked at $12.2K in Q1 2026. 11 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • GAMMA Investing held 1,941 shares of Larimar Therapeutics worth $5.92K as of Q2 2026.
  • GAMMA Investing sold 781 Larimar Therapeutics shares in Q2 2026, an estimated $3.1K.
  • Larimar Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3402 holding.
  • GAMMA Investing first reported a position in Larimar Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • GAMMA Investing's Larimar Therapeutics position peaked at $12.2K in Q1 2026.
  • 11 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.